# Phase 2/3 Study of IGSC, 20% in PIDD

> **NCT01218438** · PHASE2,PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 86 (actual)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)

## Interventions

- **BIOLOGICAL:** Immune Globulin Intravenous (Human), 10% Solution
- **DRUG:** Immune Globulin Subcutaneous (Human), 20% Solution

## Key facts

- **NCT ID:** NCT01218438
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-28
- **Primary completion:** 2015-03-13
- **Final completion:** 2015-03-13
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2021-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218438, "Phase 2/3 Study of IGSC, 20% in PIDD". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT01218438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*